JP5441690B2 - Ｈｓｐ９０活性を調節するトリアゾール化合物 - Google Patents
Ｈｓｐ９０活性を調節するトリアゾール化合物 Download PDFInfo
- Publication number
- JP5441690B2 JP5441690B2 JP2009512169A JP2009512169A JP5441690B2 JP 5441690 B2 JP5441690 B2 JP 5441690B2 JP 2009512169 A JP2009512169 A JP 2009512169A JP 2009512169 A JP2009512169 A JP 2009512169A JP 5441690 B2 JP5441690 B2 JP 5441690B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- triazol
- diol
- hydroxy
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 Triazole compounds Chemical class 0.000 title claims description 456
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 title claims description 51
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 title claims description 51
- 230000000694 effects Effects 0.000 title claims description 45
- 150000001875 compounds Chemical class 0.000 claims description 360
- 125000001072 heteroaryl group Chemical group 0.000 claims description 142
- 125000000623 heterocyclic group Chemical group 0.000 claims description 128
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 109
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 105
- 206010028980 Neoplasm Diseases 0.000 claims description 104
- 229910052757 nitrogen Inorganic materials 0.000 claims description 100
- 125000003107 substituted aryl group Chemical group 0.000 claims description 99
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 97
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 90
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 87
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 86
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 85
- 201000011510 cancer Diseases 0.000 claims description 72
- 125000001188 haloalkyl group Chemical group 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 67
- 125000001424 substituent group Chemical group 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 58
- 229910052799 carbon Inorganic materials 0.000 claims description 56
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 53
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 51
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 45
- PRILXIAAFGTMKG-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-propoxy-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C2CC(OCCC)CC2=CC=C1N1C(S)=NN=C1C1=CC(C(C)C)=C(O)C=C1O PRILXIAAFGTMKG-UHFFFAOYSA-N 0.000 claims description 43
- UPAAMKCFKSXWLK-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-methyl-1,3-dihydroisoindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3CN(C)CC3=CC=2)=C1O UPAAMKCFKSXWLK-UHFFFAOYSA-N 0.000 claims description 42
- 239000012453 solvate Substances 0.000 claims description 39
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 36
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 28
- 241000124008 Mammalia Species 0.000 claims description 25
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 25
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- 125000004076 pyridyl group Chemical group 0.000 claims description 19
- 230000015556 catabolic process Effects 0.000 claims description 18
- 238000006731 degradation reaction Methods 0.000 claims description 18
- 229960001755 resorcinol Drugs 0.000 claims description 18
- ABFCXDBXYPECGQ-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-methoxy-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C2CC(OC)CC2=CC=C1N1C(S)=NN=C1C1=CC(C(C)C)=C(O)C=C1O ABFCXDBXYPECGQ-UHFFFAOYSA-N 0.000 claims description 16
- 125000004414 alkyl thio group Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 208000027866 inflammatory disease Diseases 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 15
- 125000001544 thienyl group Chemical group 0.000 claims description 15
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
- 125000002541 furyl group Chemical group 0.000 claims description 12
- 208000026278 immune system disease Diseases 0.000 claims description 12
- 230000002062 proliferating effect Effects 0.000 claims description 12
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 10
- 210000000987 immune system Anatomy 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- CHUJYSWTCNNZKD-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-ethoxy-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C2CC(OCC)CC2=CC=C1N1C(S)=NN=C1C1=CC(C(C)C)=C(O)C=C1O CHUJYSWTCNNZKD-UHFFFAOYSA-N 0.000 claims description 8
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 7
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 208000030852 Parasitic disease Diseases 0.000 claims description 5
- JZVIEINBFWBPDJ-UHFFFAOYSA-N [2-chloro-5-hydroxy-4-(4-quinolin-5-yl-5-sulfanylidene-1H-1,2,4-triazol-3-yl)phenyl] N,N-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=C(Cl)C=C(C2=NN=C(S)N2C2=C3C=CC=NC3=CC=C2)C(O)=C1 JZVIEINBFWBPDJ-UHFFFAOYSA-N 0.000 claims description 5
- YSSCRUWTJXLQAN-UHFFFAOYSA-N [3-(dimethylcarbamoyloxy)-4-[5-(dimethylcarbamoylsulfanyl)-4-quinolin-5-yl-1,2,4-triazol-3-yl]phenyl] n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC=C1C1=NN=C(SC(=O)N(C)C)N1C1=CC=CC2=NC=CC=C12 YSSCRUWTJXLQAN-UHFFFAOYSA-N 0.000 claims description 5
- 230000017531 blood circulation Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 125000002971 oxazolyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000001425 triazolyl group Chemical group 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- LYZLSQLEAHGMQA-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindazol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3C=NN(C)C3=CC=2)=C1O LYZLSQLEAHGMQA-UHFFFAOYSA-N 0.000 claims description 3
- AHXQIXWOSLLMNU-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindazol-6-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3N(C)N=CC3=CC=2)=C1O AHXQIXWOSLLMNU-UHFFFAOYSA-N 0.000 claims description 3
- IKBGRYOHMRPODX-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-methylindazol-6-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C2=CC3=NN(C)C=C3C=C2)=C1O IKBGRYOHMRPODX-UHFFFAOYSA-N 0.000 claims description 3
- JJGWYOSOCCDKJU-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[1-methyl-2-(trifluoromethyl)benzimidazol-5-yl]-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3N=C(N(C)C3=CC=2)C(F)(F)F)=C1O JJGWYOSOCCDKJU-UHFFFAOYSA-N 0.000 claims description 3
- PLZZEEUELXPBRR-UHFFFAOYSA-N 3-(2,4-dihydroxyphenyl)-4-isoquinolin-5-yl-1H-1,2,4-triazole-5-thione Chemical compound OC1=CC(O)=CC=C1C1=NN=C(S)N1C1=CC=CC2=CN=CC=C12 PLZZEEUELXPBRR-UHFFFAOYSA-N 0.000 claims description 3
- QYVIZOQFOBGAHW-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(7-methoxy-2-methyl-1-benzofuran-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=3C=C(C)OC=3C(OC)=CC=2)=C1O QYVIZOQFOBGAHW-UHFFFAOYSA-N 0.000 claims description 3
- CXWAUYMEDCGIRL-UHFFFAOYSA-N 4-(1-benzofuran-5-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3C=COC3=CC=2)=C1O CXWAUYMEDCGIRL-UHFFFAOYSA-N 0.000 claims description 3
- RANGGRFKXIPVTL-UHFFFAOYSA-N OC1=CC(O)=CC=C1C1=NN=C(S)N1C1=CC=CC2=NC=CC=C12 Chemical compound OC1=CC(O)=CC=C1C1=NN=C(S)N1C1=CC=CC2=NC=CC=C12 RANGGRFKXIPVTL-UHFFFAOYSA-N 0.000 claims description 3
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims description 3
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 3
- VQRUPYILIOUPSA-UHFFFAOYSA-N [5-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(3-methylquinolin-5-yl)-1,2,4-triazol-3-yl]carbamic acid Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(NC(O)=O)=NN=2)C=2C3=CC(C)=CN=C3C=CC=2)=C1O VQRUPYILIOUPSA-UHFFFAOYSA-N 0.000 claims description 3
- IDKYLRUSKCDRNJ-UHFFFAOYSA-N [5-(5-ethyl-2,4-dihydroxyphenyl)-4-quinolin-5-yl-1,2,4-triazol-3-yl]urea Chemical compound C1=C(O)C(CC)=CC(C=2N(C(NC(N)=O)=NN=2)C=2C3=CC=CN=C3C=CC=2)=C1O IDKYLRUSKCDRNJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- ARZFHEBGTJGCBN-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methyl-2,3-dihydroindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3CCN(C)C3=CC=2)=C1O ARZFHEBGTJGCBN-UHFFFAOYSA-N 0.000 claims description 2
- FGOBJTIASHBAOW-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylsulfonyl-2,3-dihydroindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3CCN(C3=CC=2)S(C)(=O)=O)=C1O FGOBJTIASHBAOW-UHFFFAOYSA-N 0.000 claims description 2
- TWCMQDJOBJQALD-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-ethyl-1,3-dihydroisoindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C2CN(CC)CC2=CC=C1N1C(S)=NN=C1C1=CC(C(C)C)=C(O)C=C1O TWCMQDJOBJQALD-UHFFFAOYSA-N 0.000 claims description 2
- QOVKQTBLQIWWAQ-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-hydroxy-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3CC(O)CC3=CC=2)=C1O QOVKQTBLQIWWAQ-UHFFFAOYSA-N 0.000 claims description 2
- IYSOWEVTQCOKRS-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-methoxy-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C2CC(OC)CC2=CC=C1N1C(O)=NN=C1C1=CC(C(C)C)=C(O)C=C1O IYSOWEVTQCOKRS-UHFFFAOYSA-N 0.000 claims description 2
- UFPBXKVQPASGBJ-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-morpholin-4-yl-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3CC(CC3=CC=2)N2CCOCC2)=C1O UFPBXKVQPASGBJ-UHFFFAOYSA-N 0.000 claims description 2
- DEQQATIVSBOTAT-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-morpholin-4-yl-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3CC(CC3=CC=2)N2CCOCC2)=C1O DEQQATIVSBOTAT-UHFFFAOYSA-N 0.000 claims description 2
- ZDHCZQOEHBYDIJ-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3CC(CC3=CC=2)N2CCCC2)=C1O ZDHCZQOEHBYDIJ-UHFFFAOYSA-N 0.000 claims description 2
- CICMDMLKPGNUGX-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3CC(CC3=CC=2)N2CCCC2)=C1O CICMDMLKPGNUGX-UHFFFAOYSA-N 0.000 claims description 2
- ABTDREDRXWKWLD-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[2-(2-methoxyethyl)-1,3-dihydroisoindol-5-yl]-1H-1,2,4-triazol-5-one Chemical compound C1=C2CN(CCOC)CC2=CC=C1N1C(O)=NN=C1C1=CC(C(C)C)=C(O)C=C1O ABTDREDRXWKWLD-UHFFFAOYSA-N 0.000 claims description 2
- ZWUZGNVPEOCDPY-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3CC(CC3=CC=2)N(C)C)=C1O ZWUZGNVPEOCDPY-UHFFFAOYSA-N 0.000 claims description 2
- FTZLWLNIJKDHKV-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3CC(CC3=CC=2)N(C)C)=C1O FTZLWLNIJKDHKV-UHFFFAOYSA-N 0.000 claims description 2
- KBUMFPWDZWEKDW-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[2-(ethoxymethoxy)-2,3-dihydro-1H-inden-5-yl]-1H-1,2,4-triazol-5-one Chemical compound C1=C2CC(OCOCC)CC2=CC=C1N1C(O)=NN=C1C1=CC(C(C)C)=C(O)C=C1O KBUMFPWDZWEKDW-UHFFFAOYSA-N 0.000 claims description 2
- FSLCQIJCGLFKFD-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[2-(methoxymethoxy)-2,3-dihydro-1H-inden-5-yl]-1H-1,2,4-triazol-5-one Chemical compound C1=C2CC(OCOC)CC2=CC=C1N1C(O)=NN=C1C1=CC(C(C)C)=C(O)C=C1O FSLCQIJCGLFKFD-UHFFFAOYSA-N 0.000 claims description 2
- VSROSEZAZZFTPK-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[2-(methoxymethoxy)-2,3-dihydro-1H-inden-5-yl]-1H-1,2,4-triazole-5-thione Chemical compound C1=C2CC(OCOC)CC2=CC=C1N1C(S)=NN=C1C1=CC(C(C)C)=C(O)C=C1O VSROSEZAZZFTPK-UHFFFAOYSA-N 0.000 claims description 2
- NZQIMYQHSXBURY-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[2-[2-methoxyethyl(methyl)amino]-2,3-dihydro-1H-inden-5-yl]-1H-1,2,4-triazol-5-one Chemical compound C1=C2CC(N(C)CCOC)CC2=CC=C1N1C(O)=NN=C1C1=CC(C(C)C)=C(O)C=C1O NZQIMYQHSXBURY-UHFFFAOYSA-N 0.000 claims description 2
- NYLBDYBTQHDLEM-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-spiro[1,3-dihydroindene-2,2'-1,3-dioxolane]-5-yl-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3CC4(CC3=CC=2)OCCO4)=C1O NYLBDYBTQHDLEM-UHFFFAOYSA-N 0.000 claims description 2
- KZBBAIADDWKSFW-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-spiro[1,3-dihydroindene-2,2'-1,3-dioxolane]-5-yl-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3CC4(CC3=CC=2)OCCO4)=C1O KZBBAIADDWKSFW-UHFFFAOYSA-N 0.000 claims description 2
- MVHMXLVOELCBOL-UHFFFAOYSA-N 3-(4-aminooxy-2-hydroxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(ON)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O MVHMXLVOELCBOL-UHFFFAOYSA-N 0.000 claims description 2
- MPNRWTXNZOGWOD-UHFFFAOYSA-N 3-(5-cyclopropyl-2-hydroxyphenyl)-4-(2-methoxy-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C2CC(OC)CC2=CC=C1N1C(S)=NN=C1C(C(=CC=1)O)=CC=1C1CC1 MPNRWTXNZOGWOD-UHFFFAOYSA-N 0.000 claims description 2
- UWMHSXIXDALWEK-UHFFFAOYSA-N 3-[2,4-dihydroxy-5-(1-phenylpropan-2-yl)phenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C(O)C=C(O)C=1C(C)CC1=CC=CC=C1 UWMHSXIXDALWEK-UHFFFAOYSA-N 0.000 claims description 2
- LPFNZSCZPVMTPA-UHFFFAOYSA-N 3-[2,4-dihydroxy-5-(1-phenylpropan-2-yl)phenyl]-4-[4-[(dimethylamino)methyl]phenyl]-1H-1,2,4-triazol-5-one Chemical compound C=1C(C=2N(C(O)=NN=2)C=2C=CC(CN(C)C)=CC=2)=C(O)C=C(O)C=1C(C)CC1=CC=CC=C1 LPFNZSCZPVMTPA-UHFFFAOYSA-N 0.000 claims description 2
- YAPDERGGTZDIDD-UHFFFAOYSA-N 3-[2,4-dihydroxy-5-(2-pyrimidin-2-ylethyl)phenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=NC=CC=N1 YAPDERGGTZDIDD-UHFFFAOYSA-N 0.000 claims description 2
- YAVQWTHLHYRPDO-UHFFFAOYSA-N 3-[2,4-dihydroxy-5-[2-[3-(1-hydroxyethyl)phenyl]ethyl]phenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound CC(O)C1=CC=CC(CCC=2C(=CC(O)=C(C=3N(C(O)=NN=3)C=3C=C4C=CN(C)C4=CC=3)C=2)O)=C1 YAVQWTHLHYRPDO-UHFFFAOYSA-N 0.000 claims description 2
- KAJNJKDBBFKHEA-UHFFFAOYSA-N 3-[2,4-dihydroxy-5-[2-[4-(hydroxymethyl)phenyl]ethyl]phenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=CC=C(CO)C=C1 KAJNJKDBBFKHEA-UHFFFAOYSA-N 0.000 claims description 2
- CYNCYFQNECVDAB-UHFFFAOYSA-N 3-[2,4-dihydroxy-5-[2-[4-(methoxymethyl)phenyl]ethyl]phenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=CC(COC)=CC=C1CCC1=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C(O)C=C1O CYNCYFQNECVDAB-UHFFFAOYSA-N 0.000 claims description 2
- ZKFCOFGEFKLEJI-UHFFFAOYSA-N 3-[4-(aminomethyl)-2-hydroxy-5-propan-2-ylphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(CN)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O ZKFCOFGEFKLEJI-UHFFFAOYSA-N 0.000 claims description 2
- VNJPQTNMUDEVDL-CQSZACIVSA-N 3-[5-[(2R)-1-(2,6-difluorophenyl)propan-2-yl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C([C@@H](C)C=1C(=CC(O)=C(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)C=1)O)C1=C(F)C=CC=C1F VNJPQTNMUDEVDL-CQSZACIVSA-N 0.000 claims description 2
- VNJPQTNMUDEVDL-AWEZNQCLSA-N 3-[5-[(2S)-1-(2,6-difluorophenyl)propan-2-yl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C([C@H](C)C=1C(=CC(O)=C(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)C=1)O)C1=C(F)C=CC=C1F VNJPQTNMUDEVDL-AWEZNQCLSA-N 0.000 claims description 2
- RHEBUBOAYAFZJE-UHFFFAOYSA-N 3-[5-[1-(3,4-dimethoxyphenyl)propan-2-yl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(OC)C(OC)=CC=C1CC(C)C1=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C(O)C=C1O RHEBUBOAYAFZJE-UHFFFAOYSA-N 0.000 claims description 2
- YOWYPAYIRJDRHP-UHFFFAOYSA-N 3-[5-[1-(3-acetylphenyl)propan-2-yl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C(O)C=C(O)C=1C(C)CC1=CC=CC(C(C)=O)=C1 YOWYPAYIRJDRHP-UHFFFAOYSA-N 0.000 claims description 2
- SWZIXDXOZHFPAM-UHFFFAOYSA-N 3-[5-[1-(4-acetyl-2,6-difluorophenyl)propan-2-yl]-2,4-dihydroxyphenyl]-4-(2-methoxy-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C2CC(OC)CC2=CC=C1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1C(C)CC1=C(F)C=C(C(C)=O)C=C1F SWZIXDXOZHFPAM-UHFFFAOYSA-N 0.000 claims description 2
- XTEWVGXUILXBRD-UHFFFAOYSA-N 3-[5-[1-(4-fluorophenyl)propan-2-yl]-2,4-dihydroxyphenyl]-4-(2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C(C=2N(C(=O)NN=2)C=2C=C3CC(CC3=CC=2)N2CCCC2)=C(O)C=C(O)C=1C(C)CC1=CC=C(F)C=C1 XTEWVGXUILXBRD-UHFFFAOYSA-N 0.000 claims description 2
- HUTWBHIPLVGTRS-UHFFFAOYSA-N 3-[5-[2-(2,3-difluorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=CC=CC(F)=C1F HUTWBHIPLVGTRS-UHFFFAOYSA-N 0.000 claims description 2
- UTFPPWBVHKEJGL-UHFFFAOYSA-N 3-[5-[2-(2,5-difluorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=CC(F)=CC=C1F UTFPPWBVHKEJGL-UHFFFAOYSA-N 0.000 claims description 2
- LXVIJBLIULGMKZ-UHFFFAOYSA-N 3-[5-[2-(2,6-difluorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-[4-[2-(dimethylamino)ethyl-methylamino]-3-fluorophenyl]-1H-1,2,4-triazol-5-one Chemical compound C1=C(F)C(N(C)CCN(C)C)=CC=C1N1C(C=2C(=CC(O)=C(CCC=3C(=CC=CC=3F)F)C=2)O)=NN=C1O LXVIJBLIULGMKZ-UHFFFAOYSA-N 0.000 claims description 2
- RZYQIAZZAPNJHD-UHFFFAOYSA-N 3-[5-[2-(2-chlorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=CC=CC=C1Cl RZYQIAZZAPNJHD-UHFFFAOYSA-N 0.000 claims description 2
- YSJMVEHYDCECFV-UHFFFAOYSA-N 3-[5-[2-(2-fluorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=CC=CC=C1F YSJMVEHYDCECFV-UHFFFAOYSA-N 0.000 claims description 2
- NVRKYRDKUOYPLT-UHFFFAOYSA-N 3-[5-[2-(3,4-dimethoxyphenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(OC)C(OC)=CC=C1CCC1=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C(O)C=C1O NVRKYRDKUOYPLT-UHFFFAOYSA-N 0.000 claims description 2
- NZXCCCMEELGYTO-UHFFFAOYSA-N 3-[5-[2-(3-acetylphenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound CC(=O)C1=CC=CC(CCC=2C(=CC(O)=C(C=3N(C(O)=NN=3)C=3C=C4C=CN(C)C4=CC=3)C=2)O)=C1 NZXCCCMEELGYTO-UHFFFAOYSA-N 0.000 claims description 2
- FCLPHKYGCXZMQJ-UHFFFAOYSA-N 3-[5-[2-(3-fluorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=CC=CC(F)=C1 FCLPHKYGCXZMQJ-UHFFFAOYSA-N 0.000 claims description 2
- RQPDBBFRPKFKHH-UHFFFAOYSA-N 3-[5-[2-(4-chlorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=CC=C(Cl)C=C1 RQPDBBFRPKFKHH-UHFFFAOYSA-N 0.000 claims description 2
- ZAWYTWAULIPTJB-UHFFFAOYSA-N 3-[5-[2-(4-fluorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=CC=C(F)C=C1 ZAWYTWAULIPTJB-UHFFFAOYSA-N 0.000 claims description 2
- BORLXQGWKZWVMA-UHFFFAOYSA-N 3-[5-[2-(4-fluorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-(2-methoxy-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C2CC(OC)CC2=CC=C1N(C(NN=1)=S)C=1C(C(=CC=1O)O)=CC=1CCC1=CC=C(F)C=C1 BORLXQGWKZWVMA-UHFFFAOYSA-N 0.000 claims description 2
- XBZJSCGMCKJUGN-UHFFFAOYSA-N 3-[5-[2-[4-[(dimethylamino)methyl]phenyl]ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=CC(CN(C)C)=CC=C1CCC1=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C(O)C=C1O XBZJSCGMCKJUGN-UHFFFAOYSA-N 0.000 claims description 2
- ZHDFMGUEKCMQTQ-UHFFFAOYSA-N 3-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]benzoic acid Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C1=CC=C(C(O)=O)C=C1O ZHDFMGUEKCMQTQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- NFGUOSOETIKWCL-UHFFFAOYSA-N 4-(1,3-benzodioxol-5-yl)-3-(2-hydroxy-5-methoxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound COC1=CC=C(O)C(C=2N(C(S)=NN=2)C=2C=C3OCOC3=CC=2)=C1 NFGUOSOETIKWCL-UHFFFAOYSA-N 0.000 claims description 2
- RUADMHUKLAQNRI-UHFFFAOYSA-N 4-(1,3-benzothiazol-5-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3N=CSC3=CC=2)=C1O RUADMHUKLAQNRI-UHFFFAOYSA-N 0.000 claims description 2
- FTTSHFLWYJBKGP-UHFFFAOYSA-N 4-(1,3-benzothiazol-6-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3SC=NC3=CC=2)=C1O FTTSHFLWYJBKGP-UHFFFAOYSA-N 0.000 claims description 2
- MRZPROVKLQEKJW-UHFFFAOYSA-N 4-(2,3-dihydro-1H-inden-4-yl)-3-(2,4-dihydroxy-5-propan-2-ylphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=3CCCC=3C=CC=2)=C1O MRZPROVKLQEKJW-UHFFFAOYSA-N 0.000 claims description 2
- PPLSKQCVRCZSGR-UHFFFAOYSA-N 4-(2,3-dihydro-1H-inden-5-yl)-3-(2,4-dihydroxy-5-propan-2-ylphenyl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3CCCC3=CC=2)=C1O PPLSKQCVRCZSGR-UHFFFAOYSA-N 0.000 claims description 2
- RITMIUOKLRJPJA-UHFFFAOYSA-N 4-(2-acetyl-1,3-dihydroisoindol-5-yl)-3-(2,4-dihydroxy-5-propan-2-ylphenyl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3CN(CC3=CC=2)C(C)=O)=C1O RITMIUOKLRJPJA-UHFFFAOYSA-N 0.000 claims description 2
- IXBVYTNIEHIAHL-UHFFFAOYSA-N 4-[1-(4-aminocyclohexanecarbonyl)-2,3-dihydroindol-5-yl]-3-(2,4-dihydroxy-5-propan-2-ylphenyl)-1H-1,2,4-triazol-5-one hydrochloride Chemical compound Cl.C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3CCN(C3=CC=2)C(=O)C2CCC(N)CC2)=C1O IXBVYTNIEHIAHL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- HFFDMNXXXFZKHR-UHFFFAOYSA-N 5-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-sulfanylidene-1H-1,2,4-triazol-4-yl]-1,3-dihydroinden-2-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3CC(=O)CC3=CC=2)=C1O HFFDMNXXXFZKHR-UHFFFAOYSA-N 0.000 claims description 2
- JUWFITRPEMDLMT-UHFFFAOYSA-N 5-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-sulfanylidene-1H-1,2,4-triazol-4-yl]-1,3-dihydroindol-2-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3CC(=O)NC3=CC=2)=C1O JUWFITRPEMDLMT-UHFFFAOYSA-N 0.000 claims description 2
- PYHCDHLQGOFANF-UHFFFAOYSA-N CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)NC(=O)O Chemical compound CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)NC(=O)O PYHCDHLQGOFANF-UHFFFAOYSA-N 0.000 claims description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims 4
- 150000002009 diols Chemical class 0.000 claims 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- IOXUXEQLJVVYSJ-UHFFFAOYSA-N 3-[5-[2-(2,6-difluorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-[4-(dimethylamino)phenyl]-1H-1,2,4-triazol-5-one Chemical compound C1=CC(N(C)C)=CC=C1N1C(C=2C(=CC(O)=C(CCC=3C(=CC=CC=3F)F)C=2)O)=NN=C1O IOXUXEQLJVVYSJ-UHFFFAOYSA-N 0.000 claims 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 68
- 125000005843 halogen group Chemical group 0.000 description 61
- 230000035772 mutation Effects 0.000 description 57
- 238000000034 method Methods 0.000 description 56
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 43
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 43
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 43
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 43
- 150000001721 carbon Chemical group 0.000 description 43
- 229940002612 prodrug Drugs 0.000 description 36
- 239000000651 prodrug Substances 0.000 description 36
- 229910052717 sulfur Inorganic materials 0.000 description 35
- 102000001301 EGF receptor Human genes 0.000 description 34
- 108060006698 EGF receptor Proteins 0.000 description 32
- 208000035475 disorder Diseases 0.000 description 29
- 125000003118 aryl group Chemical group 0.000 description 28
- 208000032839 leukemia Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 27
- 125000003545 alkoxy group Chemical group 0.000 description 26
- 229910052760 oxygen Inorganic materials 0.000 description 26
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 23
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 23
- 239000002246 antineoplastic agent Substances 0.000 description 22
- YAFYQIHLDZZJGM-UHFFFAOYSA-N methyl 2-hydroxy-4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]benzoate Chemical compound COC(=O)C1=CC=C(OCCNC(=O)OC(C)(C)C)C=C1O YAFYQIHLDZZJGM-UHFFFAOYSA-N 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 19
- 125000004438 haloalkoxy group Chemical group 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 18
- 230000004913 activation Effects 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 18
- 230000003213 activating effect Effects 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 15
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 241000222722 Leishmania <genus> Species 0.000 description 14
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 13
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 13
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 13
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 13
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 13
- 208000023275 Autoimmune disease Diseases 0.000 description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 12
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 12
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 11
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 11
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 230000033115 angiogenesis Effects 0.000 description 11
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 11
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 11
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 11
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 11
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 11
- 125000001041 indolyl group Chemical group 0.000 description 11
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 11
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 11
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 10
- 125000005605 benzo group Chemical group 0.000 description 10
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 10
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 10
- 206010017758 gastric cancer Diseases 0.000 description 10
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 9
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 9
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 9
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 9
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 9
- 206010041067 Small cell lung cancer Diseases 0.000 description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 208000010668 atopic eczema Diseases 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 102000016914 ras Proteins Human genes 0.000 description 9
- 208000000587 small cell lung carcinoma Diseases 0.000 description 9
- 201000011549 stomach cancer Diseases 0.000 description 9
- 241000722885 Brettanomyces Species 0.000 description 8
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 8
- 108700020796 Oncogene Proteins 0.000 description 8
- 206010033128 Ovarian cancer Diseases 0.000 description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- KJADSPWWXRWYSQ-UHFFFAOYSA-N methyl 4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]-2-phenylmethoxybenzoate Chemical compound COC(=O)C1=CC=C(OCCNC(=O)OC(C)(C)C)C=C1OCC1=CC=CC=C1 KJADSPWWXRWYSQ-UHFFFAOYSA-N 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 8
- 229930195734 saturated hydrocarbon Natural products 0.000 description 8
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 7
- 206010018338 Glioma Diseases 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 description 7
- 125000002015 acyclic group Chemical group 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 206010025135 lupus erythematosus Diseases 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 7
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 238000010837 poor prognosis Methods 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 7
- 229960000885 rifabutin Drugs 0.000 description 7
- 102200055464 rs113488022 Human genes 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 6
- 241000224489 Amoeba Species 0.000 description 6
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- 208000032612 Glial tumor Diseases 0.000 description 6
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 6
- 208000017604 Hodgkin disease Diseases 0.000 description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 6
- 102000043136 MAP kinase family Human genes 0.000 description 6
- 108091054455 MAP kinase family Proteins 0.000 description 6
- 102000043276 Oncogene Human genes 0.000 description 6
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 6
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 6
- 241000235070 Saccharomyces Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 6
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 6
- 108700021358 erbB-1 Genes Proteins 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 208000025113 myeloid leukemia Diseases 0.000 description 6
- DTXOCJGLLMAFBX-UHFFFAOYSA-N oxo-[[1-[2-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxy]ethoxymethyl]pyridin-4-ylidene]methyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COCCOCN1C=CC(=C[NH+]=O)C=C1 DTXOCJGLLMAFBX-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 6
- 229950007866 tanespimycin Drugs 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 5
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 5
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 5
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000223960 Plasmodium falciparum Species 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 208000000389 T-cell leukemia Diseases 0.000 description 5
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 229940124650 anti-cancer therapies Drugs 0.000 description 5
- 238000011319 anticancer therapy Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 125000004663 dialkyl amino group Chemical group 0.000 description 5
- 238000006471 dimerization reaction Methods 0.000 description 5
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- 101150039808 Egfr gene Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108010044023 Ki-1 Antigen Proteins 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 101150105382 MET gene Proteins 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 241000235648 Pichia Species 0.000 description 4
- 108091008611 Protein Kinase B Proteins 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 241000223252 Rhodotorula Species 0.000 description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 4
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 4
- 229960002411 imatinib Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 108091008819 oncoproteins Proteins 0.000 description 4
- 201000010279 papillary renal cell carcinoma Diseases 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- 101150019464 ARAF gene Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 208000004736 B-Cell Leukemia Diseases 0.000 description 3
- 101150049556 Bcr gene Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010006448 Bronchiolitis Diseases 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 206010011017 Corneal graft rejection Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 201000009273 Endometriosis Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 208000034951 Genetic Translocation Diseases 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- 102220553470 Hepatocyte growth factor receptor_Y1230C_mutation Human genes 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- 206010024305 Leukaemia monocytic Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000033014 Plasma cell tumor Diseases 0.000 description 3
- 208000007452 Plasmacytoma Diseases 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 description 3
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 3
- 241000223238 Trichophyton Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000035578 autophosphorylation Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006552 constitutive activation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 201000003444 follicular lymphoma Diseases 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940080856 gleevec Drugs 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000006747 infectious mononucleosis Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 229940084651 iressa Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000003747 lymphoid leukemia Diseases 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 201000006894 monocytic leukemia Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 208000010626 plasma cell neoplasm Diseases 0.000 description 3
- 210000001978 pro-t lymphocyte Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000006379 syphilis Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 206010044325 trachoma Diseases 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- NDJPGJFQGHQYDJ-UHFFFAOYSA-N 3-(2,4-dihydroxyphenyl)-4-(5,6,7,8-tetrahydronaphthalen-1-yl)-1H-1,2,4-triazole-5-thione Chemical compound OC1=CC(O)=CC=C1C1=NN=C(S)N1C1=CC=CC2=C1CCCC2 NDJPGJFQGHQYDJ-UHFFFAOYSA-N 0.000 description 2
- MJOVNZNBOYZUES-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(1-methyl-2,3-dihydroindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3CCN(C)C3=CC=2)=C1O MJOVNZNBOYZUES-UHFFFAOYSA-N 0.000 description 2
- MDKNXOUZKIPYIW-UHFFFAOYSA-N 3-[2,5-dihydroxy-4-(hydroxymethyl)phenyl]-4-naphthalen-1-yl-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CO)=CC(O)=C1C1=NN=C(S)N1C1=CC=CC2=CC=CC=C12 MDKNXOUZKIPYIW-UHFFFAOYSA-N 0.000 description 2
- AFKBFFIARXHSKJ-UHFFFAOYSA-N 4-(1,3-benzodioxol-5-yl)-3-(2,4-dihydroxy-5-propan-2-ylphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3OCOC3=CC=2)=C1O AFKBFFIARXHSKJ-UHFFFAOYSA-N 0.000 description 2
- MHSMEFZGWDQCLQ-UHFFFAOYSA-N 4-(2,3-dihydro-1H-inden-5-yl)-3-(2,4-dihydroxy-5-propan-2-ylphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3CCCC3=CC=2)=C1O MHSMEFZGWDQCLQ-UHFFFAOYSA-N 0.000 description 2
- QUMCEVYUCICCPO-UHFFFAOYSA-N 5-[3-(5-ethyl-2,4-dihydroxyphenyl)-5-sulfanylidene-1H-1,2,4-triazol-4-yl]-1,3-dihydrobenzimidazol-2-one Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3NC(=O)NC3=CC=2)=C1O QUMCEVYUCICCPO-UHFFFAOYSA-N 0.000 description 2
- ADDLVFDOBGWGMK-UHFFFAOYSA-N 5-[3-(5-ethyl-2,4-dihydroxyphenyl)-5-sulfanylidene-1H-1,2,4-triazol-4-yl]-1,3-dihydroindol-2-one Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3CC(=O)NC3=CC=2)=C1O ADDLVFDOBGWGMK-UHFFFAOYSA-N 0.000 description 2
- VIJCSJWVEITRBE-UHFFFAOYSA-N 6-[3-(5-ethyl-2,4-dihydroxyphenyl)-5-sulfanylidene-1H-1,2,4-triazol-4-yl]-3-methyl-1,3-benzothiazol-2-one Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3SC(=O)N(C)C3=CC=2)=C1O VIJCSJWVEITRBE-UHFFFAOYSA-N 0.000 description 2
- AVUJFTYWVXBGRV-UHFFFAOYSA-N 6-[3-(5-ethyl-2,4-dihydroxyphenyl)-5-sulfanylidene-1H-1,2,4-triazol-4-yl]-3H-1,3-benzothiazol-2-one Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3SC(=O)NC3=CC=2)=C1O AVUJFTYWVXBGRV-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091007381 CBL proteins Proteins 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241001149669 Hanseniaspora Species 0.000 description 2
- 244000286779 Hansenula anomala Species 0.000 description 2
- 235000014683 Hansenula anomala Nutrition 0.000 description 2
- 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 2
- 101000825399 Homo sapiens SHC-transforming protein 1 Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 206010023330 Keloid scar Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010023421 Kidney fibrosis Diseases 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010023927 Lassa fever Diseases 0.000 description 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 2
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
- 102100021316 Mineralocorticoid receptor Human genes 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 102100022678 Nucleophosmin Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000150452 Orthohantavirus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000004422 Phospholipase C gamma Human genes 0.000 description 2
- 108010056751 Phospholipase C gamma Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100025803 Progesterone receptor Human genes 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000005663 Proto-Oncogene Proteins c-abl Human genes 0.000 description 2
- 108010045292 Proto-Oncogene Proteins c-abl Proteins 0.000 description 2
- 102000055251 Proto-Oncogene Proteins c-cbl Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 102100022340 SHC-transforming protein 1 Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 241000223104 Trypanosoma Species 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 241000235017 Zygosaccharomyces Species 0.000 description 2
- YZNCRIMHGZLBBC-UHFFFAOYSA-N [3-(dimethylcarbamoyloxy)-4-[5-(dimethylcarbamoylsulfanyl)-4-naphthalen-1-yl-1,2,4-triazol-3-yl]phenyl] n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC=C1C1=NN=C(SC(=O)N(C)C)N1C1=CC=CC2=CC=CC=C12 YZNCRIMHGZLBBC-UHFFFAOYSA-N 0.000 description 2
- 241000191335 [Candida] intermedia Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 208000004064 acoustic neuroma Diseases 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 244000309743 astrovirus Species 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002197 limbic effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000006512 mast cell neoplasm Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 235000018343 nutrient deficiency Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 108700009251 p80(NPM-ALK) Proteins 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000004214 philadelphia chromosome Anatomy 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000004765 promyelocyte Anatomy 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 102200014493 rs121909124 Human genes 0.000 description 2
- 102200055529 rs121913351 Human genes 0.000 description 2
- 102200055532 rs121913355 Human genes 0.000 description 2
- 102200055451 rs121913361 Human genes 0.000 description 2
- 102200055469 rs121913377 Human genes 0.000 description 2
- 102220066714 rs766049601 Human genes 0.000 description 2
- 229960002181 saccharomyces boulardii Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940120982 tarceva Drugs 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 239000000225 tumor suppressor protein Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- BOLSCKSQXHRCIU-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-phenylphenyl)-4-naphthalen-1-yl-1H-1,2,4-triazole-5-thione Chemical compound C1=C(C=2N(C(S)=NN=2)C=2C3=CC=CC=C3C=CC=2)C(O)=CC(O)=C1C1=CC=CC=C1 BOLSCKSQXHRCIU-UHFFFAOYSA-N 0.000 description 1
- JRCVWSUUEQNMIQ-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylbenzimidazol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3N=CN(C)C3=CC=2)=C1O JRCVWSUUEQNMIQ-UHFFFAOYSA-N 0.000 description 1
- ICFYGPQDTCGGCZ-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(3-methylbenzimidazol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3N(C)C=NC3=CC=2)=C1O ICFYGPQDTCGGCZ-UHFFFAOYSA-N 0.000 description 1
- MPKZDZVKZJKDCW-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(5,6,7,8-tetrahydronaphthalen-1-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=3CCCCC=3C=CC=2)=C1O MPKZDZVKZJKDCW-UHFFFAOYSA-N 0.000 description 1
- JEIOXPBLKVPWOM-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-quinolin-3-yl-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3C=CC=CC3=NC=2)=C1O JEIOXPBLKVPWOM-UHFFFAOYSA-N 0.000 description 1
- GUPHBOQDFCOILR-UHFFFAOYSA-N 3-(3-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-4-(1-methyl-2,3-dihydroindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1CCCC(C=C2O)=C1C=C2C1=NN=C(O)N1C1=CC=C2N(C)CCC2=C1 GUPHBOQDFCOILR-UHFFFAOYSA-N 0.000 description 1
- BGOSJCDUPWFLHY-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(2-methyl-3H-benzimidazol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3N=C(C)NC3=CC=2)=C1O BGOSJCDUPWFLHY-UHFFFAOYSA-N 0.000 description 1
- AJESLNZKMKFVMT-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-quinolin-6-yl-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3C=CC=NC3=CC=2)=C1O AJESLNZKMKFVMT-UHFFFAOYSA-N 0.000 description 1
- OMEFHNMNEZBNMM-UHFFFAOYSA-N 3-[5-(furan-2-yl)-2,4-dihydroxyphenyl]-4-naphthalen-1-yl-1H-1,2,4-triazole-5-thione Chemical compound OC1=CC(O)=C(C=2N(C(S)=NN=2)C=2C3=CC=CC=C3C=CC=2)C=C1C1=CC=CO1 OMEFHNMNEZBNMM-UHFFFAOYSA-N 0.000 description 1
- FDULWGXJSQAGPT-IKJXHCRLSA-N 3-[5-[(2R)-1-(2,6-difluorophenyl)propan-2-yl]-2,4-dihydroxyphenyl]-4-(2-methoxy-2,3-dihydro-1H-inden-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C([C@@H](C)C=1C=C(C(=CC=1O)O)C1=NN=C(O)N1C1=CC=C2CC(CC2=C1)OC)C1=C(F)C=CC=C1F FDULWGXJSQAGPT-IKJXHCRLSA-N 0.000 description 1
- BRWPOZVWKIEHLT-UHFFFAOYSA-N 3-[5-[1-(4-fluorophenyl)propan-2-yl]-2,4-dihydroxyphenyl]-4-[2-(methoxymethoxy)-2,3-dihydro-1H-inden-5-yl]-1H-1,2,4-triazol-5-one Chemical compound C1=C2CC(OCOC)CC2=CC=C1N(C(NN=1)=O)C=1C(C(=CC=1O)O)=CC=1C(C)CC1=CC=C(F)C=C1 BRWPOZVWKIEHLT-UHFFFAOYSA-N 0.000 description 1
- QGMSZIURJXFJPD-UHFFFAOYSA-N 3-[5-[2-(3-chlorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=CC=CC(Cl)=C1 QGMSZIURJXFJPD-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006027 3-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- VHOFLKSWDUMXMI-UHFFFAOYSA-N 4-(2,2-dioxo-1,3-dihydro-2-benzothiophen-5-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3CS(=O)(=O)CC3=CC=2)=C1O VHOFLKSWDUMXMI-UHFFFAOYSA-N 0.000 description 1
- WCKOTZRDDRSMAM-UHFFFAOYSA-N 4-(2H-benzotriazol-5-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3NN=NC3=CC=2)=C1O WCKOTZRDDRSMAM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XXRLJSQKKMVIOG-UHFFFAOYSA-N 5-[3-(5-ethyl-2,4-dihydroxyphenyl)-5-sulfanylidene-1H-1,2,4-triazol-4-yl]-1-methyl-3H-indol-2-one Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3CC(=O)N(C)C3=CC=2)=C1O XXRLJSQKKMVIOG-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 241000224422 Acanthamoeba Species 0.000 description 1
- 241000922028 Acanthamoeba astronyxis Species 0.000 description 1
- 241000921991 Acanthamoeba hatchetti Species 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000223602 Alternaria alternata Species 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000606646 Anaplasma Species 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000203233 Aspergillus versicolor Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000714235 Avian retrovirus Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 206010044583 Bartonella Infections Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000035462 Biphenotypic Acute Leukemia Diseases 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 208000027755 Blood autoimmune disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000908522 Borreliella Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 244000027711 Brettanomyces bruxellensis Species 0.000 description 1
- 241000722860 Brettanomyces naardenensis Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 101100447914 Caenorhabditis elegans gab-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010051226 Campylobacter infection Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000144583 Candida dubliniensis Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000512906 Candida solani Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 208000003732 Cat-scratch disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010996 Corneal degeneration Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000235036 Debaryomyces hansenii Species 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010059352 Desmoid tumour Diseases 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000019878 Eales disease Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000005668 Fusion Oncogene Proteins Human genes 0.000 description 1
- 108010084795 Fusion Oncogene Proteins Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000159512 Geotrichum Species 0.000 description 1
- RNPABQVCNAUEIY-GUQYYFCISA-N Germine Chemical compound O1[C@@]([C@H](CC[C@]23C)O)(O)[C@H]3C[C@@H](O)[C@@H]([C@]3(O)[C@@H](O)[C@H](O)[C@@H]4[C@]5(C)O)[C@@]12C[C@H]3[C@@H]4CN1[C@H]5CC[C@H](C)C1 RNPABQVCNAUEIY-GUQYYFCISA-N 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000533386 Hansenia Species 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 206010019773 Hepatitis G Diseases 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 102220553471 Hepatocyte growth factor receptor_Y1230D_mutation Human genes 0.000 description 1
- 102220553472 Hepatocyte growth factor receptor_Y1230H_mutation Human genes 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000027927 Hereditary papillary renal cell carcinoma Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010062639 Herpes dermatitis Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000763352 Homo sapiens Heat shock protein 75 kDa, mitochondrial Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101100291010 Homo sapiens MET gene Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000616502 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001661539 Kregervanrija fluxuum Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 244000207740 Lemna minor Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025219 Lymphangioma Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 108010025568 Nucleophosmin Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 description 1
- 241000521553 Pichia fermentans Species 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000639962 Rhysodes Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 102000009203 Sema domains Human genes 0.000 description 1
- 108050000099 Sema domains Proteins 0.000 description 1
- 102000014105 Semaphorin Human genes 0.000 description 1
- 108050003978 Semaphorin Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010058141 Skin graft rejection Diseases 0.000 description 1
- 241000732549 Sphaerius Species 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000223777 Theileria Species 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 241000235006 Torulaspora Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 241000390203 Trachoma Species 0.000 description 1
- 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000243774 Trichinella Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000013058 Weber syndrome Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- RROJYLNOPDVWGW-UHFFFAOYSA-N [2-ethyl-5-hydroxy-4-(4-naphthalen-2-yl-5-oxo-1H-1,2,4-triazol-3-yl)phenyl] N,N-dimethylcarbamate Chemical compound OC1=C(C=C(C(=C1)OC(N(C)C)=O)CC)C1=NN=C(N1C1=CC2=CC=CC=C2C=C1)O RROJYLNOPDVWGW-UHFFFAOYSA-N 0.000 description 1
- PRUZMHKFKPRUKZ-UHFFFAOYSA-N [4-[4-(2,3-difluorophenyl)-5-sulfanylidene-1H-1,2,4-triazol-3-yl]-2-ethyl-5-hydroxyphenyl] N,N-dimethylcarbamate Chemical compound CCC1=C(OC(=O)N(C)C)C=C(O)C(=C1)C1=NNC(=S)N1C1=C(F)C(F)=CC=C1 PRUZMHKFKPRUKZ-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000035362 autoimmune disorder of the nervous system Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000004339 autoimmune neuropathy Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 206010004145 bartonellosis Diseases 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 101150048834 braF gene Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000007293 brain stem infarction Diseases 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001945 cyclooctatrienyl group Chemical group C1(=CC=CC=CCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 201000006827 desmoid tumor Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 206010049444 fibromatosis Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 108010020084 germin Proteins 0.000 description 1
- RNPABQVCNAUEIY-UHFFFAOYSA-N germine Natural products O1C(C(CCC23C)O)(O)C3CC(O)C(C3(O)C(O)C(O)C4C5(C)O)C12CC3C4CN1C5CCC(C)C1 RNPABQVCNAUEIY-UHFFFAOYSA-N 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 230000001401 hemangioblastic effect Effects 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000003905 indoor air pollution Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000016491 infection by Trypanosoma rhodesiense Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000013256 infectious meningitis Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005468 isobutylenyl group Chemical group 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000024799 morphogenesis of a branching structure Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108091008569 nuclear steroid hormone receptors Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004287 null lymphocyte Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009589 pathological growth Effects 0.000 description 1
- 201000002689 pediatric hepatocellular carcinoma Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000007757 pro-survival signaling Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001350 reed-sternberg cell Anatomy 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000022021 regulation of cell morphogenesis Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 102220198013 rs1057519824 Human genes 0.000 description 1
- 102220004855 rs121913243 Human genes 0.000 description 1
- 102220197908 rs121913244 Human genes 0.000 description 1
- 102220197954 rs121913245 Human genes 0.000 description 1
- 102220004853 rs121913246 Human genes 0.000 description 1
- 102220067223 rs121913247 Human genes 0.000 description 1
- 102200055453 rs121913340 Human genes 0.000 description 1
- 102200055517 rs121913348 Human genes 0.000 description 1
- 102200055463 rs121913369 Human genes 0.000 description 1
- 102220004849 rs121913668 Human genes 0.000 description 1
- 102220004850 rs121913669 Human genes 0.000 description 1
- 102220004851 rs121913670 Human genes 0.000 description 1
- 102220004854 rs121913673 Human genes 0.000 description 1
- 102220004765 rs121913675 Human genes 0.000 description 1
- 102220004856 rs121913676 Human genes 0.000 description 1
- 102220004857 rs121913677 Human genes 0.000 description 1
- 102220216833 rs768678989 Human genes 0.000 description 1
- 102220059662 rs786202724 Human genes 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 201000008759 sweat gland cancer Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 201000008753 synovium neoplasm Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940066765 systemic antihistamines substituted ethylene diamines Drugs 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000005233 tubule cell Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 239000004066 vascular targeting agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80842506P | 2006-05-25 | 2006-05-25 | |
| US80824806P | 2006-05-25 | 2006-05-25 | |
| US80825606P | 2006-05-25 | 2006-05-25 | |
| US60/808,248 | 2006-05-25 | ||
| US60/808,425 | 2006-05-25 | ||
| US60/808,256 | 2006-05-25 | ||
| PCT/US2007/012524 WO2007139955A2 (en) | 2006-05-25 | 2007-05-25 | Triazole compounds that modulate hsp90 activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009538320A JP2009538320A (ja) | 2009-11-05 |
| JP2009538320A5 JP2009538320A5 (enExample) | 2010-07-15 |
| JP5441690B2 true JP5441690B2 (ja) | 2014-03-12 |
Family
ID=38656998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512169A Expired - Fee Related JP5441690B2 (ja) | 2006-05-25 | 2007-05-25 | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8318790B2 (enExample) |
| EP (1) | EP2034996A2 (enExample) |
| JP (1) | JP5441690B2 (enExample) |
| AU (1) | AU2007267847B2 (enExample) |
| CA (1) | CA2653222A1 (enExample) |
| TW (1) | TW200804313A (enExample) |
| WO (1) | WO2007139955A2 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI297335B (en) | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI332943B (en) | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI330079B (en) | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
| PL1781604T3 (pl) | 2004-06-23 | 2014-01-31 | Synta Pharmaceuticals Corp | Sole bis(tiohydrazydoamidu) do leczenia nowotworów |
| EP2298748B1 (en) * | 2004-11-18 | 2016-07-20 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| BRPI0610219A2 (pt) | 2005-04-15 | 2010-06-08 | Synta Pharmaceuticals Corp | métodos de tratamento de um ser humano com cáncer e composição de farmacêutica |
| US7608635B2 (en) | 2005-08-12 | 2009-10-27 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
| EP1928846B1 (en) | 2005-08-18 | 2014-06-04 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| US20080027047A1 (en) * | 2006-05-25 | 2008-01-31 | Weiwen Ying | Compounds that modulate HSP90 activity and methods for identifying same |
| EP2034995A2 (en) | 2006-05-25 | 2009-03-18 | Synta Pharmaceuticals Corporation | Method for treating proliferative disorders associated with protooncogene products |
| AU2007267803B2 (en) | 2006-05-25 | 2011-08-25 | Synta Pharmaceuticals Corp. | Method for treating non-Hodgkin's lymphoma |
| TW200804313A (en) | 2006-05-25 | 2008-01-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
| CA2653329C (en) | 2006-05-25 | 2018-01-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AU2007284537B2 (en) * | 2006-08-17 | 2012-04-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| US8609720B2 (en) | 2006-08-21 | 2013-12-17 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| US20110046125A1 (en) * | 2006-10-19 | 2011-02-24 | Synta Pharmaceuticals Corp. | Method for treating infections |
| CN101679319B (zh) | 2007-02-08 | 2014-07-09 | 辛塔医药品有限公司 | 用于治疗增生性病症如癌症的三唑类化合物 |
| US8993608B2 (en) | 2007-03-12 | 2015-03-31 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase II |
| TWI438199B (zh) | 2007-08-13 | 2014-05-21 | Synta Pharmaceuticals Corp | 調控ｈｓｐ９０活性的三唑化合物 |
| EP2198068A1 (en) * | 2007-10-05 | 2010-06-23 | Johnson Matthey Public Limited Company | Improved metal protection |
| US9156836B2 (en) * | 2008-05-16 | 2015-10-13 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate HSP90 activity |
| US8450500B2 (en) | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| WO2009158026A1 (en) | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
| EP2323737A2 (en) | 2008-08-08 | 2011-05-25 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| ES2415234T3 (es) * | 2008-08-08 | 2013-07-24 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad Hsp90 |
| WO2010144345A1 (en) * | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| CN102713606A (zh) * | 2009-11-13 | 2012-10-03 | 无限制药股份有限公司 | 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法 |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| JP2014520808A (ja) | 2011-07-07 | 2014-08-25 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０阻害化合物を用いた癌の治療 |
| CA2841069C (en) * | 2011-07-08 | 2021-11-23 | Sloan-Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
| WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| EP2780010A1 (en) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| NZ702169A (en) | 2012-05-25 | 2016-10-28 | Berg Llc | The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome |
| CN102977012B (zh) * | 2012-12-20 | 2015-06-03 | 江苏弘和药物研发有限公司 | 4-溴吡啶-2-甲酸甲酯的合成方法 |
| ES2660249T3 (es) | 2012-12-20 | 2018-03-21 | Inception 2, Inc. | Compuestos de tipo triazolona y sus usos |
| JP2016529311A (ja) | 2013-09-06 | 2016-09-23 | インセプション ２、 インコーポレイテッド | トリアゾロン化合物類及びそれらの使用 |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| WO2015188198A2 (en) | 2014-06-06 | 2015-12-10 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
| AU2016263564B2 (en) | 2015-05-20 | 2019-12-05 | Amgen Inc. | Triazole agonists of the APJ receptor |
| US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
| US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
| WO2018097944A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| MA52487A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
| CA3103166A1 (en) * | 2018-06-29 | 2020-01-02 | F. Hoffmann-La Roche Ag | Compounds |
| CN113121505B (zh) * | 2021-03-02 | 2023-03-07 | 中国人民解放军海军军医大学 | 一种具有抗真菌与抗肿瘤双重作用的三唑酮类化合物及应用 |
| CN114539098B (zh) * | 2022-02-26 | 2024-05-24 | 青岛大学 | 一种双功能hdac6抑制剂、合成方法及应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB928919A (en) * | 1960-08-16 | 1963-06-19 | Bellon Labor Sa Roger | Triazole derivatives and a process for their preparation |
| US4269846A (en) * | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| JPS5910574A (ja) | 1982-07-07 | 1984-01-20 | Fujisawa Pharmaceut Co Ltd | トリアゾ−ル誘導体およびその製造法 |
| FR2546887B1 (fr) | 1983-05-30 | 1985-08-30 | Paris 7 Universite | Procede de preparation de dihydro-2,4 triazol-1,2,4 thiones-3 disubstituees en positions 4 et 5 et nouveaux composes pouvant etre prepares par ce procede |
| US4740568A (en) * | 1985-04-09 | 1988-04-26 | Minnesota Mining And Manufacturing Company | Triazolinethione-containing polymer |
| US4624995A (en) * | 1985-04-09 | 1986-11-25 | Minnesota Mining And Manufacturing Company | Triazolinethione-containing polymer |
| US5436252A (en) * | 1986-12-19 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders |
| US5006650A (en) * | 1987-02-11 | 1991-04-09 | The Upjohn Company | Novel N-1 substituted beta-lactams as antibiotics |
| DE3729070A1 (de) * | 1987-09-01 | 1989-03-09 | Bayer Ag | Substituierte triazolinone |
| SK278998B6 (sk) * | 1991-02-01 | 1998-05-06 | Merck Sharp & Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu, spôsob i |
| DE69330713T2 (de) * | 1992-03-13 | 2002-07-04 | Merck Sharp & Dohme Ltd., Hoddesdon | Imidazol-, triazol- und tetrazolderivate |
| TW218017B (enExample) * | 1992-04-28 | 1993-12-21 | Takeda Pharm Industry Co Ltd | |
| DE4222771A1 (de) * | 1992-07-10 | 1994-01-13 | Bayer Ag | Heterocyclyltriazolinone |
| DE4303376A1 (de) * | 1993-02-05 | 1994-08-11 | Bayer Ag | Substituierte Triazolinone |
| DE4303676A1 (de) * | 1993-02-09 | 1994-08-11 | Bayer Ag | 1-Aryltriazolin(thi)one |
| US5538988A (en) * | 1994-04-26 | 1996-07-23 | Martinez; Gregory R. | Benzocycloalkylazolethione derivatives |
| US5489598A (en) * | 1994-06-08 | 1996-02-06 | Warner-Lambert Company | Cytoprotection utilizing aryltriazol-3-thiones |
| JP3372365B2 (ja) * | 1994-08-19 | 2003-02-04 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料およびそれを用いた画像形成方法 |
| DE19521162A1 (de) * | 1995-06-09 | 1996-12-12 | Bayer Ag | N-Aryl-1,2,4-triazolin-5-one |
| TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| JP3788676B2 (ja) * | 1997-11-11 | 2006-06-21 | 富士写真フイルム株式会社 | 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子 |
| WO1999046246A1 (de) * | 1998-03-09 | 1999-09-16 | Basf Aktiengesellschaft | Hetarylsubstituierte benzylphenylether, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen und tierischen schädlingen |
| JP2000284412A (ja) | 1999-03-30 | 2000-10-13 | Fuji Photo Film Co Ltd | 熱現像写真材料 |
| US6492406B1 (en) * | 1999-05-21 | 2002-12-10 | Astrazeneca Ab | Pharmaceutically active compounds |
| WO2002066447A1 (en) * | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors |
| JP4102124B2 (ja) | 2001-08-01 | 2008-06-18 | 富士フイルム株式会社 | ハロゲン化銀乳剤およびハロゲン化銀写真感光材料 |
| CA2468184A1 (fr) | 2001-11-28 | 2003-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R A.S.) | Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicament |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| JP2005084612A (ja) * | 2003-09-11 | 2005-03-31 | Fuji Photo Film Co Ltd | ハロゲン化銀乳剤、ハロゲン化銀感光材料、および熱現像感光材料 |
| WO2005044194A2 (en) | 2003-10-28 | 2005-05-19 | Pharmacia Corporation | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR |
| WO2005097758A1 (en) | 2004-03-26 | 2005-10-20 | Amphora Discovery Corporation | Certain triazole-based compounds, compositions, and uses thereof |
| EP2298748B1 (en) * | 2004-11-18 | 2016-07-20 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| DE102005007304A1 (de) * | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
| JP5044730B2 (ja) | 2005-03-09 | 2012-10-10 | 日本化薬株式会社 | 新規なｈｓｐ９０阻害剤 |
| US7608635B2 (en) | 2005-08-12 | 2009-10-27 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
| EP1928846B1 (en) | 2005-08-18 | 2014-06-04 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CA2618724A1 (en) | 2005-08-18 | 2007-02-22 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate hsp90 activity |
| DE102006023337A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | Triazolderivate II |
| CA2653329C (en) | 2006-05-25 | 2018-01-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| TW200804313A (en) | 2006-05-25 | 2008-01-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
| US20080027047A1 (en) | 2006-05-25 | 2008-01-31 | Weiwen Ying | Compounds that modulate HSP90 activity and methods for identifying same |
| AU2007267803B2 (en) | 2006-05-25 | 2011-08-25 | Synta Pharmaceuticals Corp. | Method for treating non-Hodgkin's lymphoma |
| TWI490212B (zh) | 2006-05-25 | 2015-07-01 | Synta Pharmaceuticals Corp | 調節ｈｓｐ９０活性之三唑化合物 |
| TW200806637A (en) | 2006-05-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Synthesis of triazole compounds that modulate HSP90 activity |
| EP2034995A2 (en) | 2006-05-25 | 2009-03-18 | Synta Pharmaceuticals Corporation | Method for treating proliferative disorders associated with protooncogene products |
| AU2007284537B2 (en) | 2006-08-17 | 2012-04-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| US20110046125A1 (en) | 2006-10-19 | 2011-02-24 | Synta Pharmaceuticals Corp. | Method for treating infections |
| WO2008057246A2 (en) | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| CN101679319B (zh) | 2007-02-08 | 2014-07-09 | 辛塔医药品有限公司 | 用于治疗增生性病症如癌症的三唑类化合物 |
| US8993608B2 (en) | 2007-03-12 | 2015-03-31 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase II |
| WO2008118391A2 (en) | 2007-03-27 | 2008-10-02 | Synta Pharmaceuticals Corp. | Triazinone and diazinone derivatives useful as hsp90 inhibitors |
| WO2008153730A2 (en) | 2007-05-25 | 2008-12-18 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with mutations in c-met |
| TWI438199B (zh) | 2007-08-13 | 2014-05-21 | Synta Pharmaceuticals Corp | 調控ｈｓｐ９０活性的三唑化合物 |
| US9156836B2 (en) | 2008-05-16 | 2015-10-13 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate HSP90 activity |
| US8450500B2 (en) | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| WO2009158026A1 (en) | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
| ES2415234T3 (es) | 2008-08-08 | 2013-07-24 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad Hsp90 |
| EP2323737A2 (en) | 2008-08-08 | 2011-05-25 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AU2011302344B2 (en) | 2010-09-13 | 2015-01-15 | Synta Pharmaceuticals Corp. | HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients |
-
2007
- 2007-05-25 TW TW096118677A patent/TW200804313A/zh unknown
- 2007-05-25 CA CA002653222A patent/CA2653222A1/en not_active Abandoned
- 2007-05-25 WO PCT/US2007/012524 patent/WO2007139955A2/en not_active Ceased
- 2007-05-25 US US11/807,201 patent/US8318790B2/en not_active Expired - Fee Related
- 2007-05-25 EP EP07809199A patent/EP2034996A2/en not_active Withdrawn
- 2007-05-25 JP JP2009512169A patent/JP5441690B2/ja not_active Expired - Fee Related
- 2007-05-25 AU AU2007267847A patent/AU2007267847B2/en not_active Ceased
-
2012
- 2012-01-13 US US13/350,296 patent/US8927548B2/en active Active
-
2014
- 2014-12-31 US US14/587,531 patent/US20150183771A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150183771A1 (en) | 2015-07-02 |
| WO2007139955A8 (en) | 2008-02-14 |
| TW200804313A (en) | 2008-01-16 |
| CA2653222A1 (en) | 2007-12-06 |
| AU2007267847A1 (en) | 2007-12-06 |
| US8927548B2 (en) | 2015-01-06 |
| EP2034996A2 (en) | 2009-03-18 |
| US20120122869A1 (en) | 2012-05-17 |
| AU2007267847B2 (en) | 2012-04-12 |
| WO2007139955A2 (en) | 2007-12-06 |
| JP2009538320A (ja) | 2009-11-05 |
| WO2007139955A3 (en) | 2008-08-21 |
| US8318790B2 (en) | 2012-11-27 |
| US20080090887A1 (en) | 2008-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5596543B2 (ja) | Ｈｓｐ９０活性を調節するトリアゾール化合物 | |
| JP5410965B2 (ja) | Ｈｓｐ９０活性を調節するトリアゾール化合物 | |
| JP5441691B2 (ja) | Ｈｓｐ９０活性を調節するトリアゾール化合物 | |
| JP5529004B2 (ja) | Ｈｓｐ９０阻害剤として有用なトリアジノンおよびジアジノン誘導体 | |
| JP5523839B2 (ja) | 癌などの増殖障害の治療に有用なトリアゾール化合物 | |
| US8318790B2 (en) | Triazole compounds that modulate HSP90 activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100524 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100524 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121001 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121002 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130104 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130401 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130508 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130806 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131101 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131127 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131217 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |